Get the Stockscreener App
1.52
2.70%
0.04
After Hours:
1.53
0.01
+0.66%
Geron Corp stock is traded at $1.52, with a volume of 24.14M.
It is up +2.70% in the last 24 hours and up +10.14% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.48
Open:
$1.47
24h Volume:
24.14M
Relative Volume:
1.65
Market Cap:
$968.12M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-4.75
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+4.83%
1M Performance:
+10.14%
6M Performance:
-63.11%
1Y Performance:
-56.20%
1-Day Range:
$1.40
$1.60
1-Week Range:
$1.40
$1.60
52-Week Range:
$1.17
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.52 | 923.53M | 29.48M | -201.19M | -216.50M | -0.32 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Nuveen Asset Management LLC Purchases 14,657 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron showcases RYTELO benefits at oncology meetings By Investing.com - Investing.com South Africa
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles By Investing.com - Investing.com South Africa
Geron showcases RYTELO benefits at oncology meetings - Investing.com
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program - Yahoo Finance
Geron’s SWOT analysis: oncology firm’s stock faces growth hurdles - Investing.com
Geron Corp stockholders approve equity plan amendments By Investing.com - Investing.com India
Geron Corp stockholders approve equity plan amendments - Investing.com
BNP Paribas Financial Markets Decreases Stock Holdings in Geron Co. (NASDAQ:GERN) - Defense World
25,148 Shares in Geron Co. (NASDAQ:GERN) Purchased by Lazard Asset Management LLC - Defense World
Geron Co. (NASDAQ:GERN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bank of America Corp DE Boosts Stock Position in Geron Co. (NASDAQ:GERN) - Defense World
Ameriprise Financial Inc. Buys 247,018 Shares of Geron Co. (NASDAQ:GERN) - Defense World
Geron Grants $522K Worth of Stock Options and RSUs: New Employee Compensation Details Revealed - Stock Titan
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Stifel Financial Corp Increases Position in Geron Co. (NASDAQ:GERN) - Defense World
Geron Corp Stock (GERN): Demand Recovery on the Rise - Value The Markets
Northern Trust Corp Has $19.76 Million Stake in Geron Co. (NASDAQ:GERN) - Defense World
Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now - Insider Monkey
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Business Wire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - Stockhouse
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - GlobeNewswire
Research Analysts Set Expectations for Geron FY2028 Earnings - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - GlobeNewswire Inc.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse
Geron slips as Scotiabank downgrades on sales challenges for blood cancer drug - MSN
Geron (GERN) Faces Downgrade Amid Rytelo Rollout Concerns - GuruFocus
Geron stock is downgraded at Scotiabank (GERN:NASDAQ) - Seeking Alpha
Geron (GERN) Price Target Reduced by Wedbush Amid Uptake Challen - GuruFocus
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GER - GuruFocus
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GERN Stock News - GuruFocus
Geron (GERN) Faces Downgrade Amid Rytelo Launch Challenges | GERN Stock News - GuruFocus
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Geron Corporation(GERN) Shareholders - PR Newswire
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... - Yahoo Finance
Geron: Q1 Earnings Snapshot - New Haven Register
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Growth Initiatives - GuruFocus
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Geron Stock Crept Higher Today - Barchart.com
Geron Corporation (GERN) Targets RYTELO Growth Amid Revenue Dip - GuruFocus
Geron Corp. Posts Narrower Loss In Q1 - Nasdaq
Earnings call transcript: Geron meets Q1 2025 EPS forecast, stock dips - Investing.com
Geron (GERN) Reports Q1 Revenue Below Expectations, Focuses on R - GuruFocus
Geron (GERN) Posts Narrower Q1 Loss Amid Revenue Surge - GuruFocus
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):